CMR Surgical, the private company developing a next-generation robotic system for universal minimal access surgery, today announces the successful completion of its first round of clinical cadaveric trials.
All clinical targets were achieved with the system demonstrating surgical activities in the pelvic, upper gastrointestinal (“GI”) and colorectal surgical areas. Procedures were filmed both internally and externally and collected data will inform further cadaveric, animal, and first-in-human trials. Cadaveric trials followed the successful completion of bench tests with full-size simulators.
The trials were held at The Evelyn Cambridge Surgical Training Centre and conducted by CMR’s Medical Director Mark Slack and other members of CMR’s Medical Affairs team.
Mark Slack commented: “The successful completion of preliminary cadaveric trials is a significant milestone in the planned development and regulatory processes. The trials allowed us to demonstrate the advanced capabilities of the CMR system including haptic force feedback, fully wristed 5mm instruments and the ability to perform a wide range of multi-quadrant minimal access procedures including urological, gynaecological, upper GI and colorectal procedures, all with standard port placements making the future transition to robotics as easy as possible for surgeons.”
“Within the next decade I now believe surgical robotic systems will become a standard feature in operating theatres and a critical extension of the modern day surgeon. With its small and light weight form factor, ease of set up and versatile design the CMR system is strongly positioned to extend the benefits of minimal access surgery to a greater number of patients.”
Mark Slack is a Consultant Surgeon and the Head of Urogynaecology at Addenbrooke’s Hospital, Cambridge University Hospitals.